康恩貝(600572.SH):全資子公司恩替卡韋片獲得藥品註冊證書
格隆匯8月7日丨康恩貝(600572.SH)公佈,公司全資子公司浙江金華康恩貝生物製藥有限公司(簡稱:金華康恩貝)收到國家藥品監督管理局核准簽發的規格為0.5mg、1mg的恩替卡韋片《藥品註冊證書》。
恩替卡韋片是一種鳥嘌呤核苷類似物,對乙型肝炎病毒(HBV)多聚酶具有抑制作用,適用於病毒複製活躍、血清丙氨酸氨基轉氨酶(ALT)持續升高或肝臟組織學顯示有活動性病變的慢性成人乙型肝炎的治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.